



## Axonal Pathology: From Cellular Mechanism to Therapy Targets

Guest Editor:

### Dr. Lu-Shiun Her

Department of Life Sciences,  
National Cheng Kung University,  
Tainan 70101, Taiwan

Deadline for manuscript  
submissions:

**closed (15 June 2023)**

### Message from the Guest Editor

Loss of neurons represents the pathological event in neurodegenerative diseases. In the nervous system, axons convey the communication between neurons. The great sizes of axons make them vulnerable to various insults. Thus far, the majority of studies for potential mechanisms and therapeutic targets for neurodegenerative disorders have focused on events that occur in the cell bodies of neurons. However, white matter defects have been identified as an early neuropathological event, leading to axonal degeneration and eventual death of neurons in many neurodegenerative diseases.

Therefore, we invite authors to submit original research and review articles that focus on the molecular mechanisms and therapeutic potential of axonal pathology. Potential topics include but are not limited to:

- Dystrophic neurite/axonal degeneration
- Cytoskeleton integrity
- Microtubule-based transport
- Ubiquitin–proteasome system
- Autophagy–lysosome system
- Growth factor signaling
- Mitochondria





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI